New method to identify early stage lung cancer identified
Senior authors Charles Powell, MD, MBA, Janice and Coleman Rabin, Professor of Medicine and Dean of the Department, said: “Methods for the diagnosis and treatment of early-stage lung adenocarcinoma are evolving and are based on advances in understanding the biology and clinical activity of these tumors. in Lung, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai. “Our work uses new network approaches, in collaboration with Sema4, to identify markers of invasiveness and identify drugs that can halt the progression of these cancers. This will contribute to improving understanding and outcomes for this cancer.”
They performed molecular profiling of early-stage lung cancer samples with RNA sequencing and identified specific genes involved in tumor aggressiveness. Researchers from Sema4 used novel genomic network approaches to identify key network regulators and therapeutic drugs to demonstrate that targeting the signaling pathway does reduce the spread of lung cancer and improve survival. They identified and tested aurora kinase inhibitors, including AMG900, as an effective treatment to halt lung cancer progression in models.
The researchers encourage further validation and clinical trials on human tumours. Future studies will examine opportunities to similarly interfere with the signaling of immune cells or other cells in the surrounding tumor stroma, the researchers say. Cancer depends on interactions between tumor cells and surrounding cells.
Researchers from Weill Cornell Medicine-NewYork-Presbyterian Hospital and Sema4, a patient-centered health intelligence company, contributed to this study. This work was supported by grants from the National Institutes of Health (R01CA163772, R01HL130826 and R01CA240342), the New York State Stem Cell Science Program (C34052GG), American Thoracic Society Foundation-Sponsorship Unlimited (ATS-2017-24), American Lung Association Northeastern Lung Cancer Detection Award (LCD-504985) and Department of Defense (W81XWH-19-1-0613).